HC Wainwright & Co. Reiterates Buy on Adverum Biotechnologies, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on Adverum Biotechnologies (NASDAQ:ADVM) and maintained a $30 price target.
August 13, 2024 | 6:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on Adverum Biotechnologies and maintained a $30 price target.
The reiteration of a Buy rating and the maintenance of a $30 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100